Splicing reprogramming of TRAIL/DISC-components sensitizes lung cancer cells to TRAIL-mediated apoptosis.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
17 03 2021
17 03 2021
Historique:
received:
14
10
2020
accepted:
22
02
2021
revised:
19
02
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
6
10
2021
Statut:
epublish
Résumé
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selective killing of cancer cells underlines its anticancer potential. However, poor tolerability and resistance underscores the need to identify cancer-selective TRAIL-sensitizing agents. Apigenin, a dietary flavonoid, sensitizes lung cancer cell lines to TRAIL. It remains unknown, however, whether apigenin sensitizes primary lung cancer cells to TRAIL and its underlying mechanisms. Here we show that apigenin reprograms alternative splicing of key TRAIL/death-inducing-signaling-complex (DISC) components: TRAIL Death Receptor 5 (DR5) and cellular-FLICE-inhibitory-protein (c-FLIP) by interacting with the RNA-binding proteins hnRNPA2 and MSI2, resulting in increased DR5 and decreased c-FLIP
Identifiants
pubmed: 33731677
doi: 10.1038/s41419-021-03567-1
pii: 10.1038/s41419-021-03567-1
pmc: PMC7969956
doi:
Substances chimiques
TNF-Related Apoptosis-Inducing Ligand
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
287Références
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J. Clin. 68, 7–30 (2018).
doi: 10.3322/caac.21442
pubmed: 29313949
Balata, H. et al. Prevention and early detection for NSCLC: advances in thoracic oncology 2018. J. Thorac. Oncol. 14, 1513–1527 (2019).
pubmed: 31228621
doi: 10.1016/j.jtho.2019.06.011
Kim, E. Y., Yu, J. S., Yang, M. & Kim, A. K. Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5. Mol. Cells 35, 32–40 (2013).
pubmed: 23224239
doi: 10.1007/s10059-013-2175-2
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
doi: 10.3322/caac.21590
pubmed: 31912902
Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest 104, 155–162 (1999).
pubmed: 10411544
pmcid: 408479
doi: 10.1172/JCI6926
Dimberg, L. Y. et al. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32, 1341–1350 (2013).
pubmed: 22580613
doi: 10.1038/onc.2012.164
Trivedi, R. & Mishra, D. P. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol. 5, 69 (2015).
pubmed: 25883904
pmcid: 4382980
doi: 10.3389/fonc.2015.00069
Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821 (1997).
pubmed: 9242611
doi: 10.1126/science.277.5327.818
Kischkel, F. C. et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611–620 (2000).
pubmed: 10894161
doi: 10.1016/S1074-7613(00)80212-5
Sprick, M. R. et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599–609 (2000).
pubmed: 10894160
doi: 10.1016/S1074-7613(00)80211-3
de Miguel, D., Lemke, J., Anel, A., Walczak, H. & Martinez-Lostao, L. Onto better TRAILs for cancer treatment. Cell Death Differ. 23, 733–747 (2016).
pubmed: 26943322
pmcid: 4832109
doi: 10.1038/cdd.2015.174
Lemke, J., von Karstedt, S., Zinngrebe, J. & Walczak, H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 21, 1350–1364 (2014).
pubmed: 24948009
pmcid: 4131183
doi: 10.1038/cdd.2014.81
Kaminskyy, V. O. et al. Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling. Cell Death Dis. 4, e522 (2013).
pubmed: 23470529
pmcid: 3613829
doi: 10.1038/cddis.2013.51
Zhuang, H. et al. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions. J. Mol. Med (Berl.) 91, 219–235 (2013).
doi: 10.1007/s00109-012-0947-3
Guo, F. et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105, 1246–1255 (2005).
pubmed: 15388581
doi: 10.1182/blood-2004-05-2041
Bin, L., Li, X., Xu, L. G. & Shu, H. B. The short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis. FEBS Lett. 510, 37–40 (2002).
pubmed: 11755527
doi: 10.1016/S0014-5793(01)03222-7
Sudhakaran, M., Sardesai, S. & Doseff, A. I. Flavonoids: New frontier for immuno-regulation and breast cancer control. Antioxidants 8, 1–27 (2019).
doi: 10.3390/antiox8040103
Cardenas, H. et al. Dietary apigenin exerts immune-regulatory activity in vivo by reducing NF-kappaB activity, halting leukocyte infiltration and restoring normal metabolic function. Int. J. Mol. Sci. 17, 1–17 (2016).
doi: 10.3390/ijms17030323
Gonzalez-Mejia, M. E., Voss, O. H., Murnan, E. J. & Doseff, A. I. Apigenin-induced-apoptosis of leukemia cells is mediated by a bimodal and differentially regulated residue-specific phosphorylation of Heat Shock Protein 27. Cell Death Dis. 1, e64 (2010).
pubmed: 21364669
pmcid: 3032520
doi: 10.1038/cddis.2010.41
Nicholas, C. et al. Apigenin blocks lipopolysaccharide-induced lethality in vivo and pro-inflammatory cytokines expression by inactivating NF-κB through the suppression of p65 phosphorylation. J. Immunol. 179, 7121–7127 (2007).
pubmed: 17982104
doi: 10.4049/jimmunol.179.10.7121
Vargo, M. A. et al. Apigenin-induced-apoptosis is mediated by the activation of PKCδ and caspases in leukemia cells. Biochem Pharm. 72, 681–692 (2006).
pubmed: 16844095
doi: 10.1016/j.bcp.2006.06.010
Liu, L. Z. et al. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol. Pharm. 68, 635–643 (2005).
doi: 10.1124/mol.105.011254
Lu, H. F. et al. Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax- and Bcl-2-triggered mitochondrial pathway. Int J. Oncol. 36, 1477–1484 (2010).
pubmed: 20428772
Horinaka, M. et al. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 5, 945–951 (2006).
pubmed: 16648565
doi: 10.1158/1535-7163.MCT-05-0431
Chen, M. et al. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Sci. Rep. 6, 35468 (2016).
pubmed: 27752089
pmcid: 5067669
doi: 10.1038/srep35468
Oishi, M. et al. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS ONE 8, e55922 (2013).
pubmed: 23431365
pmcid: 3576345
doi: 10.1371/journal.pone.0055922
Arango, D. et al. Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets. Proc. Natl Acad. Sci. USA 110, E2153–E2162 (2013).
pubmed: 23697369
doi: 10.1073/pnas.1303726110
pmcid: 3683737
Pereira, B., Billaud, M. & Almeida, R. RNA-binding proteins in cancer: old players and new cctors. Trends Cancer 3, 506–528 (2017).
pubmed: 28718405
doi: 10.1016/j.trecan.2017.05.003
Di, C. et al. Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell Death Differ. 26, 1181–1194 (2019).
pubmed: 30464224
doi: 10.1038/s41418-018-0231-3
Gadgeel, S. M., Ali, S., Philip, P. A., Wozniak, A. & Sarkar, F. H. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer 115, 2165–2176 (2009).
pubmed: 19288574
doi: 10.1002/cncr.24250
Zhang, X. Y., Zhang, X. D., Borrow, J. M., Nguyen, T. & Hersey, P. Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells. J. Biol. Chem. 279, 10606–10614 (2004).
pubmed: 14688276
doi: 10.1074/jbc.M308211200
Boatright, K. M., Deis, C., Denault, J. B., Sutherlin, D. P. & Salvesen, G. S. Activation of caspases-8 and -10 by FLIP(L). Biochem J. 382, 651–657 (2004).
pubmed: 15209560
pmcid: 1133822
doi: 10.1042/BJ20040809
Golan-Gerstl, R. et al. Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71, 4464–4472 (2011).
pubmed: 21586613
doi: 10.1158/0008-5472.CAN-10-4410
Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5, 157–163 (1999).
pubmed: 9930862
doi: 10.1038/5517
Hostetler, G. et al. Flavone deglycosylation increases their anti-inflammatory activity and absorption. Mol. Nutr. Food Res 56, 558–569 (2012).
pubmed: 22351119
pmcid: 4070292
doi: 10.1002/mnfr.201100596
Arango, D. et al. Dietary apigenin reduces LPS-induced expression of miR-155 restoring immune balance during inflammation. Mol. Nutr. Food Res 59, 763–772 (2015).
pubmed: 25641956
pmcid: 7955240
doi: 10.1002/mnfr.201400705
Deng, D. & Shah, K. TRAIL of hope meeting resistance in cancer. Trends Cancer 6, 989–1001 (2020).
pubmed: 32718904
doi: 10.1016/j.trecan.2020.06.006
pmcid: 7688478
Saleh, A., Srinivasula, S. M., Balkir, L., Robbins, P. D. & Alnemri, E. S. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol. 2, 476–483 (2000).
pubmed: 10934467
doi: 10.1038/35019510
Gotoh, T., Terada, K., Oyadomari, S. & Mori, M. hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ. 11, 390–402 (2004).
pubmed: 14752510
doi: 10.1038/sj.cdd.4401369
Stankiewicz, A. R., Lachapelle, G., Foo, C. P., Radicioni, S. M. & Mosser, D. D. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J. Biol. Chem. 280, 38729–38739 (2005).
pubmed: 16172114
doi: 10.1074/jbc.M509497200
Hartwig, T. et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol. Cell 65, 730–742 (2017). e735.
pubmed: 28212753
pmcid: 5316415
doi: 10.1016/j.molcel.2017.01.021
Venables, J. P. et al. MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation. Nat. Commun. 4, 2480 (2013).
pubmed: 24048253
doi: 10.1038/ncomms3480
Kudinov, A. E., Karanicolas, J., Golemis, E. A. & Boumber, Y. Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets. Clin. Cancer Res 23, 2143–2153 (2017).
pubmed: 28143872
pmcid: 5413399
doi: 10.1158/1078-0432.CCR-16-2728
Katsimpoula, S. et al. Overexpression of hnRNPA2/B1 in bronchoscopic specimens: a potential early detection marker in lung cancer. Anticancer Res 29, 1373–1382 (2009).
pubmed: 19414390
Xi, L. et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 36, 6535–6547 (2008).
pubmed: 18927117
pmcid: 2582617
doi: 10.1093/nar/gkn697
O’Brien, K., Matlin, A. J., Lowell, A. M. & Moore, M. J. The biflavonoid isoginkgetin is a general inhibitor of Pre-mRNA splicing. J. Biol. Chem. 283, 33147–33154 (2008).
pubmed: 18826947
pmcid: 2586251
doi: 10.1074/jbc.M805556200
Sivaramakrishnan, M. et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat. Commun. 8, 1476 (2017).
pubmed: 29133793
pmcid: 5684323
doi: 10.1038/s41467-017-01559-4
Pawellek, A. et al. Characterisation of the biflavonoid hinokiflavone as a pre-mRNA splicing modulator that inhibits SENP. Elife 6, 1–36 (2017).
doi: 10.7554/eLife.27402
Wu, P. S., Yen, J. H., Kou, M. C. & Wu, M. J. Luteolin and apigenin attenuate 4-hydroxy-2-nonenal-mediated cell death through modulation of UPR, Nrf2-ARE and MAPK pathways in PC12 cells. PLoS ONE 10, e0130599 (2015).
pubmed: 26087007
pmcid: 4472230
doi: 10.1371/journal.pone.0130599
Chiba, M., Ariga, H. & Maita, H. A splicing reporter tuned to non-AG acceptor sites reveals that luteolin enhances the recognition of non-canonical acceptor sites. Chem. Biol. Drug Des. 87, 275–282 (2016).
pubmed: 26348996
doi: 10.1111/cbdd.12656
Kurata, M. et al. Inhibition of mRNA maturation by compounds which have a flavonoid skeleton. Biochem Mol. Biol. 2, 46–53 (2017).
doi: 10.11648/j.bmb.20170204.13
Voss, O. H. et al. Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J. Biol. Chem. 282, 25088–25099 (2007).
pubmed: 17597071
doi: 10.1074/jbc.M701740200
Mao, R. F. et al. OLA1 protects cells in heat shock by stabilizing HSP70. Cell Death Dis. 4, e491 (2013).
pubmed: 23412384
pmcid: 3734832
doi: 10.1038/cddis.2013.23
Voss, O. H., Kim, S., Wewers, M. D. & Doseff, A. I. Regulation of monocyte apoptosis by the Protein Kinase Cδ-dependent phosphorylation of caspase-3. J. Biol. Chem. 280, 17371–17379 (2005).
pubmed: 15716280
doi: 10.1074/jbc.M412449200